ihonkohdien
Ihonkohdien, also known as 1-Methyl-4-(3-hydroxyphenyl)-1H-pyrazolo[3,4-b]pyridine, is a synthetic cannabinoid receptor agonist. It was first synthesized in 2011 by a research group at the University of Strasbourg. Ihonkohdien is structurally related to other synthetic cannabinoids, such as JWH-018 and JWH-073, and it acts as a potent agonist at the cannabinoid CB1 and CB2 receptors.
Ihonkohdien has been studied for its potential therapeutic applications, including as an analgesic, anti-inflammatory, and anti-emetic
However, like other synthetic cannabinoids, ihonkohdien has also been associated with adverse effects, including psychoactive properties,
Ihonkohdien is typically synthesized through a multi-step process involving the reaction of various precursors, including 3-hydroxyphenylpyrazole